Sanofi's ambitions in immuno-oncology are spearheaded by its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), and the drugmaker has been acquiring new assets that may have ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback